Amgen Bolsters Research and Development with Appointment of New Executive Director
Biotech giant Amgen has appointed Raphaella Thorson as Executive Director of Research and Development (R&D) Knowledge and Learning. This strategic move comes as Amgen continues to advance scientific innovation and digital transformation across its R&D organization.
Thorson brings over 17 years of experience in the biotechnology and pharmaceutical industry, having held various leadership positions at AstraZeneca and MedImmune. She will lead Amgen's R&D Knowledge and Learning function, driving enterprise learning strategies, knowledge management, and capability development to support research, clinical development, quality, and regulatory excellence.
Amgen's appointment of Thorson reflects its continued investment in building a future-ready learning ecosystem that enables innovation while supporting compliance across its global R&D operations. With her extensive expertise in R&D learning, GxP capability development, and learning technologies, Thorson is well-equipped to drive Amgen's research and development efforts forward.
About Amgen: The company has consistently been recognized as one of the world's most innovative organizations, including being named one of Fast Company's World's Most Innovative Companies and one of Forbes' America's Best Large Employers. Amgen has a strong track record of pioneering innovations across various therapeutic areas, including oncology, cardiovascular disease, osteoporosis, inflammation, nephrology, and rare diseases.